Avinash Desai

825 total citations
20 papers, 501 citations indexed

About

Avinash Desai is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Avinash Desai has authored 20 papers receiving a total of 501 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Molecular Biology and 7 papers in Hematology. Recurrent topics in Avinash Desai's work include Multiple Myeloma Research and Treatments (5 papers), Protein Degradation and Inhibitors (4 papers) and Retinal Diseases and Treatments (3 papers). Avinash Desai is often cited by papers focused on Multiple Myeloma Research and Treatments (5 papers), Protein Degradation and Inhibitors (4 papers) and Retinal Diseases and Treatments (3 papers). Avinash Desai collaborates with scholars based in United States, Netherlands and Belgium. Avinash Desai's co-authors include Maneesha Mehra, Ravi Potluri, Helgi van de Velde, Nikhil C. Munshi, Jessica Vermeulen, Annette Lam, Tahamtan Ahmadi, Saad Z. Usmani, Juan José Lahuerta and Andrew Cakana and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Avinash Desai

19 papers receiving 485 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Avinash Desai United States	8	309	295	260	68	49	20	501
Anna Grazia Recchia Italy	16	166 0.5×	302 1.0×	265 1.0×	96 1.4×	26 0.5×	38	653
Christy Samaras United States	13	189 0.6×	264 0.9×	302 1.2×	16 0.2×	17 0.3×	57	437
Francesco Mendicino Italy	12	106 0.3×	224 0.8×	152 0.6×	26 0.4×	13 0.3×	52	433
Giambattista Bertani Italy	8	70 0.2×	302 1.0×	188 0.7×	42 0.6×	11 0.2×	20	460
Mohamed Elhamri France	14	159 0.5×	323 1.1×	181 0.7×	19 0.3×	51 1.0×	44	507
Hyewon Lee South Korea	12	150 0.5×	220 0.7×	127 0.5×	62 0.9×	8 0.2×	38	424
Yogesh Jethava United States	10	151 0.5×	249 0.8×	206 0.8×	38 0.6×	7 0.1×	50	423
Maria Niniraki Greece	9	59 0.2×	127 0.4×	86 0.3×	27 0.4×	35 0.7×	12	335
Dawn Colburn United States	10	160 0.5×	135 0.5×	252 1.0×	78 1.1×	5 0.1×	20	524
R. Mauritz Netherlands	9	130 0.4×	77 0.3×	124 0.5×	37 0.5×	9 0.2×	14	427

Countries citing papers authored by Avinash Desai

Since Specialization

Citations

This map shows the geographic impact of Avinash Desai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Avinash Desai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Avinash Desai more than expected).

Fields of papers citing papers by Avinash Desai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Avinash Desai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Avinash Desai. The network helps show where Avinash Desai may publish in the future.

Co-authorship network of co-authors of Avinash Desai

This figure shows the co-authorship network connecting the top 25 collaborators of Avinash Desai. A scholar is included among the top collaborators of Avinash Desai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Avinash Desai. Avinash Desai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Allen, Kevin J., Jason Li, Madhuri Vusirikala, et al.. (2025). Abstract 594: Lintuzumab-Ac225 has potent mutation agnostic antileukemic activity in preclinical models of AML. Cancer Research. 85(8_Supplement_1). 594–594.

Desai, Avinash, et al.. (2021). Efficacy of Antenatal Magnesium Sulfate for Neuroprotection in Extreme Prematurity: A Comparative Observational Study. The Journal of Obstetrics and Gynecology of India. 72(S1). 36–47. 7 indexed citations

Lin, Huamao Mark, et al.. (2018). Economic burden of brain metastases in patients with anaplastic lymphoma kinase positive (ALK+) non–small cell lung cancer (NSCLC) receiving second-line ALK inhibitors.. Journal of Clinical Oncology. 36(30_suppl). 13–13. 1 indexed citations

Desai, Avinash, et al.. (2017). A STUDY ON CONSUMER AWARENESS IN BANKING SECTOR AFTER THE MERGER WITH SPECIAL REFERENCE TO STATE BANK OF INDIA AND STATE BANK OF INDORE. PARIPEX-INDIAN JOURNAL OF RESEARCH. 1 indexed citations

Desai, Avinash, et al.. (2017). Pericardial effusion and cardiac tamponade following percutaneously inserted central line insertion in an extremely low-birth-weight baby: Case report and successful management. Indian Journal of Critical Care Medicine. 21(1). 57–59. 2 indexed citations

Copher, Ronda, Oluwakayode Adejoro, Stacey DaCosta Byfield, et al.. (2017). Second or none: Many patients treated for refractory differentiated thyroid cancer with small molecular kinase inhibitors do not receive a second line of therapy.. Journal of Clinical Oncology. 35(15_suppl). e17589–e17589. 1 indexed citations

Usmani, Saad Z., Tahamtan Ahmadi, Annette Lam, et al.. (2016). Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD. The Oncologist. 21(11). 1355–1361. 104 indexed citations

Desai, Avinash, et al.. (2016). Mishaps in the Washroom-A Rare Case. Journal of Neurology & Neurophysiology. 7(5). 1 indexed citations

Johnson, Kevin B., et al.. (2015). Patient-Relevant Experiences and Impacts of Acute Myeloid Leukemia: Evidence from Online Social Networks-Based Qualitative Research. Blood. 126(23). 4523–4523. 3 indexed citations

10.

Mateos, María‐Victoria, Sara Bringhen, PG Richardson, et al.. (2014). Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. Haematologica. 99(6). 1114–1122. 35 indexed citations

11.

Munshi, Nikhil C., Maneesha Mehra, Helgi van de Velde, et al.. (2014). Use of a claims database to characterize and estimate the incidence rate for Castleman disease. Leukemia & lymphoma. 56(5). 1252–1260. 105 indexed citations

12.

Sonneveld, Pieter, Hartmut Goldschmidt, Laura Rosiñol, et al.. (2013). Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials. Journal of Clinical Oncology. 31(26). 3279–3287. 150 indexed citations

13.

Mehra, Maneesha, et al.. (2012). Use of a Claims Database to Characterize and Estimate the Incidence of Castleman's Disease. Blood. 120(21). 4253–4253. 9 indexed citations

14.

Miguel, Jesús F. San, Paul G. Richardson, Robert Z. Orlowski, et al.. (2011). Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM). Blood. 118(21). 2933–2933. 8 indexed citations

15.

Wainberg, Zev A., Judy Dering, Charles Ginther, et al.. (2008). Identification of predictive markers of response in colorectal cancer following treatment with dasatinib, an orally active tyrosine kinase inhibitor of ABL and SRC. Journal of Clinical Oncology. 26(15_suppl). 14688–14688. 1 indexed citations

16.

Connolly, Brian R., Avinash Desai, Charles García, Edgar L. Thomas, & Michael J. Gast. (2006). Squalamine lactate for exudative age-related macular degeneration.. PubMed. 19(3). 381–91, vi. 18 indexed citations

17.

Ciulla, Thomas A., Carl D. Regillo, Avinash Desai, et al.. (2005). A Phase II, Multi–Center, Randomized, Controlled, Masked Study of the Effects of Squalamine Lactate in Combination With Visudyne® in Patients With Subfoveal Choroidal Neovascularization Associated With Age–Related Macular Degeneration. 46(13). 2363–2363. 4 indexed citations

18.

García, Charles, Brian R. Connolly, E. Louise Thomas, et al.. (2005). A Phase 2 Multi–Dose Pharmacokinetic Study of MSI–1256F (Squalamine Lactate) for the Treatment of Subfoveal Choroidal Neovascularization Associated With Age–Related Macular Degeneration (AMD). 46(13). 206–206. 4 indexed citations

19.

García, Charles, Hugo Quiroz–Mercado, Sami H. Uwaydat, et al.. (2004). A Phase I/II Trial of Intravenous Squalamine Lactate for Treatment of Choroidal Neovascularization in Age Related Macular Degeneration (ARMD).. Investigative Ophthalmology & Visual Science. 45(13). 2362–2362. 6 indexed citations

20.

Herbst, Roy S., Lisa A. Hammond, David P. Carbone, et al.. (2003). A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.. PubMed. 9(11). 4108–15. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact